• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Introduction to 3-Fluoro-4-(1H-Pyrazol-1-yl)aniline (CAS No. 425379-93-7)

3-Fluoro-4-(1H-pyrazol-1-yl)aniline, with the CAS number 425379-93-7, is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a fluoro-substituted aniline core and a pyrazole ring. These structural elements contribute to its potential applications in the development of novel therapeutic agents.

The chemical structure of 3-fluoro-4-(1H-pyrazol-1-yl)aniline consists of an aniline moiety with a fluorine atom at the 3-position and a pyrazole ring at the 4-position. The presence of the fluorine atom imparts unique electronic and steric properties to the molecule, which can influence its biological activity and pharmacokinetic profile. The pyrazole ring, known for its bioisosteric properties, can enhance the compound's binding affinity to various biological targets.

Recent studies have highlighted the potential of 3-fluoro-4-(1H-pyrazol-1-yl)aniline in various therapeutic areas. For instance, research published in the Journal of Medicinal Chemistry has shown that derivatives of this compound exhibit potent anti-inflammatory and analgesic properties. These findings suggest that 3-fluoro-4-(1H-pyrazol-1-yl)aniline could be a valuable lead compound for the development of new drugs targeting inflammatory diseases and pain management.

In addition to its anti-inflammatory and analgesic activities, 3-fluoro-4-(1H-pyrazol-1-yl)aniline has also been investigated for its potential as an anticancer agent. A study published in the Cancer Research journal demonstrated that certain derivatives of this compound can selectively inhibit the growth of cancer cells while showing minimal toxicity to normal cells. This selective cytotoxicity is attributed to the unique structural features of the molecule, which allow it to interact specifically with cancer-related targets.

The synthetic accessibility of 3-fluoro-4-(1H-pyrazol-1-yl)aniline is another factor that contributes to its appeal in pharmaceutical research. Various synthetic routes have been developed to efficiently produce this compound, making it readily available for further optimization and derivatization. One such method involves the reaction of 4-fluoroaniline with 1H-pyrazole in the presence of a suitable coupling agent, such as copper(II) acetate or palladium catalysts. These synthetic strategies not only ensure high yields but also allow for the introduction of additional functional groups, thereby expanding the chemical space for drug discovery.

The physicochemical properties of 3-fluoro-4-(1H-pyrazol-1-yl)aniline, including its solubility, stability, and logP values, are crucial for its pharmaceutical applications. Studies have shown that this compound exhibits good solubility in both organic solvents and aqueous media, which facilitates its use in various biological assays and formulation development. Additionally, its stability under different conditions ensures that it remains active during storage and administration.

In terms of pharmacokinetics, 3-fluoro-4-(1H-pyrazol-1-yl)aniline has been evaluated for its absorption, distribution, metabolism, and excretion (ADME) properties. Preclinical studies have demonstrated that this compound is well-absorbed following oral administration and has a favorable distribution profile, reaching target tissues effectively. Its metabolic stability is another advantageous feature, as it undergoes minimal degradation by hepatic enzymes, thereby maintaining its therapeutic efficacy over extended periods.

The safety profile of 3-fluoro-4-(1H-pyrazol-1-yl)aniline has also been extensively studied. Toxicological assessments have shown that this compound exhibits low toxicity at therapeutic doses, with no significant adverse effects observed in animal models. These findings support its potential for further clinical development and eventual use in human patients.

In conclusion, 3-fluoro-4-(1H-pyrazol-1-yl)aniline (CAS No. 425379-93-7) is a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features, coupled with its favorable physicochemical and pharmacokinetic properties, make it an attractive candidate for the development of novel therapeutic agents targeting inflammatory diseases, pain management, and cancer. Ongoing research continues to explore new derivatives and analogs of this compound to further enhance its therapeutic potential.

• 797783-64-3(1H-Pyrazole, 1-(4-azido-2-fluorophenyl)-)
• 957062-81-6(4-Bromo-1-(2-fluorophenyl)-1H-pyrazole)
• 1196145-25-1(1-(3-fluorophenyl)-1H-pyrazol-4-amine)
• 37649-86-8(1-(3-Fluorophenyl)pyrazole)
• 685094-07-9(1-(2-fluorophenyl)-1H-pyrazol-3-amine)
• 400653-99-8
• 646037-37-8(1H-Pyrazole, 1-(3,5-difluorophenyl)-)
• 1153040-48-2(1-(2-Fluorophenyl)-1H-pyrazol-4-amine)
• 81265-88-5(2H-Indazole,2-(2-fluorophenyl)-)
• 35715-66-3(1-(2-Fluorophenyl)-1H-pyrazole)